Notatki do odcinka
Why does fewer than one in ten drugs that enter clinical trials ever reach patients — and what can be done about it before a compound ever gets there?
In this episode of Cognitio, Richard Knight, toxicologist and co-founder of Apconix, a nonclinical consultancy and lab working with biotech and pharma companies worldwide. Richard spent twenty years in global safety assessment at AstraZeneca, including several years as oncology safety lead, before starting Apconix a decade ago.
Richard makes the case that toxicology shouldn't be treated as a late-stage hurdle, but as a design consideration…
Strona: podcasters.spotify.com

